万邦医药
(301520)
| 流通市值：9.24亿 | | | 总市值：27.46亿 |
| 流通股本：2242.30万 | | | 总股本：6666.67万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 209,425,876.45 | 146,838,210.56 | 71,052,156.02 | 379,090,705.99 |
| 营业收入 | 209,425,876.45 | 146,838,210.56 | 71,052,156.02 | 379,090,705.99 |
| 利息收入 | 0 | 0 | - | 0 |
| 已赚保费 | 0 | 0 | - | 0 |
| 手续费及佣金收入 | 0 | 0 | - | 0 |
| 二、营业总成本 | 206,411,326.1 | 137,088,912.58 | 67,004,139.61 | 319,913,163.19 |
| 营业成本 | 145,708,733.9 | 95,846,446.79 | 48,583,371.84 | 229,050,743.65 |
| 利息支出 | 0 | 0 | - | 0 |
| 手续费及佣金支出 | 0 | 0 | - | 0 |
| 退保金 | 0 | 0 | - | 0 |
| 赔付支出净额 | 0 | 0 | - | 0 |
| 提取保险合同准备金净额 | 0 | 0 | - | 0 |
| 保单红利支出 | 0 | 0 | - | 0 |
| 分保费用 | 0 | 0 | - | 0 |
| 税金及附加 | 1,250,927.72 | 901,988.21 | 371,004.48 | 1,562,089.71 |
| 销售费用 | 5,623,066.89 | 4,070,649.63 | 1,870,131.71 | 4,878,851.9 |
| 管理费用 | 17,786,102.5 | 13,016,538.49 | 5,787,453.48 | 26,888,628.7 |
| 研发费用 | 36,961,787.88 | 24,006,530.24 | 10,765,309.15 | 60,681,199.45 |
| 财务费用 | -919,292.79 | -753,240.78 | -373,131.05 | -3,148,350.22 |
| 其中:利息费用 | 0 | 0 | - | - |
| 其中:利息收入 | 936,587.48 | 768,688.47 | 376,411.05 | 3,176,130.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 16,310,483.36 | 11,515,386.15 | 5,464,055.56 | 7,034,391.6 |
| 加:投资收益 | 7,945,781.97 | 2,638,364.11 | 2,149,076.26 | 21,155,290.01 |
| 净敞口套期收益 | 0 | 0 | - | 0 |
| 汇兑收益 | 0 | 0 | - | 0 |
| 资产处置收益 | 0 | 0 | - | 16,439.76 |
| 资产减值损失(新) | -1,414,335.51 | -402,055.93 | -709,902.51 | -2,021,480.27 |
| 信用减值损失(新) | -1,394,314.75 | -1,978,197.32 | 345,692.79 | -3,798,567.06 |
| 其他收益 | 5,968,067.64 | 3,661,603.68 | 472,798.25 | 5,476,209.8 |
| 四、营业利润 | 30,430,233.06 | 25,184,398.67 | 11,769,736.76 | 87,039,826.64 |
| 加:营业外收入 | 7,042.37 | 7,042.36 | 8,042.09 | 2,507,520.95 |
| 减:营业外支出 | 50,023.71 | 50,000 | 50,000 | 50,619.32 |
| 五、利润总额 | 30,387,251.72 | 25,141,441.03 | 11,727,778.85 | 89,496,728.27 |
| 减:所得税费用 | -2,723,367.4 | -1,669,964.35 | -121,510.2 | 3,966,050.76 |
| 六、净利润 | 33,110,619.12 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,110,619.12 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,110,619.12 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 |
| 少数股东损益 | 0 | 0 | - | - |
| 扣除非经常损益后的净利润 | 8,449,166.49 | 12,327,047.7 | 5,358,872.31 | 55,787,750.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.5 | 0.4 | 0.18 | 1.28 |
| (二)稀释每股收益 | 0.5 | 0.4 | 0.18 | 1.28 |
| 八、其他综合收益 | 0 | 0 | - | 0 |
| 归属于母公司股东的其他综合收益 | 0 | 0 | - | - |
| 九、综合收益总额 | 33,110,619.12 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 |
| 归属于母公司股东的综合收益总额 | 33,110,619.12 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 |
| 归属于少数股东的综合收益总额 | 0 | 0 | - | - |
| 公告日期 | 2025-10-23 | 2025-08-26 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |